切换至 "中华医学电子期刊资源库"
高级检索
中华医学超声杂志（电子版）

中华医学超声杂志（电子版） ›› 2018, Vol. 15 ›› Issue (06) : 433 -439. doi: 10.3877/cma.j.issn.1672-6448.2018.06.008

所属专题： 文献；

心血管超声影像学

Tei指数评价蒽环类药物对恶性肿瘤患儿的右心损害
韩若凌1,†(), 尹笑笑1, 赵娜1   
  1. 1. 050011　石家庄，河北医科大学第四医院超声科
  • 收稿日期:2017-09-08 出版日期:2018-06-01
  • 通信作者: 韩若凌
  • 基金资助:
    河北省自然科学基金(H2015206405)

The value of ultrasonography in evaluating right ventricular function in children after antharcycline therapy

Ruoling Han1,†(), Xiaoxiao Yin1, Na Zhao1   

  1. 1. Department of Ultrasound, The Forth Hospital of Hebei Medical University, Shijiazhuang 050011, China
  • Received:2017-09-08 Published:2018-06-01
  • Corresponding author: Ruoling Han
  • About author:
    Corresponding author: Han Ruoling, Email:
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

韩若凌, 尹笑笑, 赵娜. Tei指数评价蒽环类药物对恶性肿瘤患儿的右心损害[J]. 中华医学超声杂志（电子版）, 2018, 15(06): 433-439.

Ruoling Han, Xiaoxiao Yin, Na Zhao. The value of ultrasonography in evaluating right ventricular function in children after antharcycline therapy[J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2018, 15(06): 433-439.

目的

分析Tei指数评价恶性肿瘤患儿使用蒽环类药物后右心功能损害的价值。

方法

选择2015年6月至2016年12月河北医科大学第四医院收治的恶性肿瘤患儿34例（恶性肿瘤组），年龄2~14岁。同时选择同期该院体检的排除先天性心脏病、代谢型疾病及心血管损伤的非肿瘤儿童17名作为健康对照组，年龄2~13岁。对用药前、药物累计剂量为100、200、250 mg/m2时恶性肿瘤组患儿及健康对照组儿童进行超声心动图检查，测得三尖瓣舒张早期峰值流速E、舒张晚期峰值流速A；三尖瓣环收缩期运动速度峰值s′、舒张早期运动速度峰值e′及舒张晚期运动速度峰值a′；右心室侧壁及室间隔基底段等容收缩期（ICTR、ICTS）、等容舒张期（IRTR、IRTS）、射血时间（ETR、ETS），由公式TeiR=（ICTR＋IRTR）/ETR，TeiS=（ICTS＋IRTS）/ETS，Tei=（TeiR+TeiS）/2计算Tei指数及其他相关指标。采用t检验比较恶性肿瘤组患儿与健康对照组儿童用药前一般临床资料及常规超声心动图、组织多普勒及Tei指数相关指标；采用方差分析比较用药前及不同累计剂量时恶性肿瘤组患儿常规超声心动图、组织多普勒及Tei指数相关指标，进一步组间两两比较采用LSD-t检验；采用双变量Pearson相关分析法分析蒽环类药物累计剂量与ICTR、TeiR、TeiS及Tei指数的相关性；采用直线回归分析法分析蒽环类药物累计剂量与Tei指数之间的关系。

结果

恶性肿瘤组患儿与健康对照组儿童用药前一般临床资料及常规超声心动图、组织多普勒及Tei指数相关指标等差异均无统计学意义。用药前及不同累计剂量时肿瘤组患儿常规超声心动图、组织多普勒指标、ICTS、IRTS、ETS、IRTR、ETR差异均无统计学意义。累计剂量达200、250 mg/m2时ICTR、TeiR、Tei指数均高于用药前［（54±5）ms、（57±5）ms vs （50±5）ms，（0.40±0.03）、（0.41±0.03）vs （0.38±0.03），（0.39±0.03）、（0.41±0.03） vs （0.37±0.03）］，且差异均有统计学意义（t=3.406，P=0.001；t=6.256，P<0.001；t=2.875，P=0.003；t=4.625，P<0.001；t=2.857，P=0.004；t=5.000，P<0.001）；而其余任意2个时间点间ICTR、TeiR、Tei指数差异均无统计学意义。累计剂量达250 mg/m2时TeiS高于用药前［（0.40±0.04） vs （0.37±0.04）］，且差异有统计学意义（t=3.300，P=0.001）；而其余任意2个时间点间TeiS差异均无统计学意义。蒽环类药物累计剂量与ICTR、TeiR、Tei指数呈正相关（r=0.482、0.397、0.417，P均<0.001），而与TeiS相关性较小（r=0.279，P=0.001）。Tei指数随着蒽环类药物剂量的增加而升高，回归方程为Y=0.000 13X＋0.368。

结论

组织多普勒中的TeiS、ICTR、TeiR、Tei指数较常规超声心动图指标更敏感，且右心Tei指数随着蒽环类药物累计剂量的增加而升高。

关键词: 超声心动描记术, 药物疗法, 癌, Tei指数, 心室功能，右, 心房功能，右, 儿童
Objective

To explore the value of Tei index in evaluating right ventricular function in children with malignant disease after antharcycline therapy.

Methods

Thirty-four children in the malignant tumor group who were suffering from malignant tumor and hospitalized in the Fourth Affiliated Hospital of Hebei Medical University between June 2015 to December 2016 were evaluated for clinical cardiotoxicity. At the same time, 17 healthy non-tumor children taking examination during the same period in the same hospital without the congenital heart diseases, metabolic diseases, and cardiovascular injuries were selected as the healthy control group. We assessed right cardiac injury with echocardiography in the two group before the first cure, at cumulative doses of anthracycline 100, 200 and 250 mg/m2, respectively. The parameters included tricuspid E velocity and tricuspid A velocity; tricuspid annulus peak systolic velocity (s′), tricuspid annulus early peak diastolic velocity (e′) and tricuspid annulus atrial contraction (a′); isovolumic contraction time of right ventricular lateral wall basal segment (ICTR), isovolumic relaxation time of right ventricular lateral wall basal segment (IRTR) and ejection time of right ventricular lateral wall basal segment (ETR); isovolumic contraction time of interventricular septum basal segment (ICTS), isovolumic relaxation time of interventricular septum basal segment (IRTS) and ejection time of interventricular septum basal segment (ETS), then calculated Tei index and other relevant parameters by formula TeiR=(ICTR+ IRTR)/ETR, TeiS=(ICTS+ IRTS)/ETS, Tei=(TeiR+ TeiS)/2. In the case group before anthracycline chemotherapy and the control group, the t-test was used to compare the general clinical data, conventional echocardiography, tissue doppler and Tei index related parameters of children, and the sex ratios were compared with the chi-test. Variance analysis was used to compare conventional echocardiography, tissue Doppler and Tei index related parameters before the first cure, at cumulative doses of anthracycline 100, 200 and 250 mg/m2 in the malignant tumor group, and LSD-t test was used for further comparisons between groups. The bivariate Pearson correlation analysis was used to analyze the correlation between the cumulative dose of anthracycline and ICTR, TeiR, TeiS and Tei index. The linear regression analysis was used to analyze the relationship between cumulative dose of anthracycline and Tei index.

Results

Compared to control group, there were no significant differences in the basic clinical data and ultrasonic parameters in the case group. There were no significant differences in conventional ultrasonic and tissue Doppler indicators, ICTS, IRTS, ETS, IRTR and ETR before the first cure, at cumulative doses of anthracycline 100, 200 and 250 mg/m2. ICTR, TeiR and Tei increased at cumulative doses of anthracycline 200 and 250 mg/m2 compared with before antharcycline therapy, and the differences were statistically significant [(54±5) ms, (57±5) ms vs (50±5) ms; (0.40±0.03), (0.41±0.03) vs (0.38±0.03); (0.39±0.03), (0.41±0.03) vs (0.37±0.03); t=3.406, P=0.001; t=6.256, P<0.001; t=2.875, P=0.003; t=4.625, P<0.001; t=2.857, P=0.004; t=5.000, P<0.001]. There were no significant differences at the other two timepoints. TeiS increased at cumulative doses of anthracycline 250 mg/m2 compared with before antharcycline therapy, and the difference was statistically sifnificant [(0.40±0.04) vs (0.37±0.04), t=3.300, P=0.001]. There were no significant differences at the other two timepoints. Drug cumulative doses were positively correlated with ICTR, TeiR and Tei (r=0.482, 0.397, 0.417, all P<0.001), and had poor correlation with TeiS (r=0.279, P=0.001). Tei increased with the drug cumulative doses, and the linear regression equation could be demonstrated as Y=0.000 13X+ 0.368.

Conclusion

Tissue Doppler parameters, such as TeiS, ICTR, TeiR, Tei, were more sensitive in detecting abnormalities of right cardiac function, particularly for Tei index, which increased with the accumulated dose.

Key words: Echocardiography, Drug therapy, Carcinoma, Tei index, Ventricular function, right, Atrial function, right, Child
图3 组织多普勒测得右心室侧壁s′、e′、a′、等容收缩期、等容舒张期、射血时间
表1 蒽环类药物剂量换算表
蒽环类药物 转换系数 5%发生心脏毒性的蒽环类药物累计剂量
阿霉素 1 450 mg/m2
表阿霉素 0.5 900 mg/m2
柔红霉素 0.5 935 mg/m2
去甲氧柔红霉素 2 225 mg/m2
米托蒽醌 2.2 200 mg/m2
表2 恶性肿瘤组患儿与健康对照组儿童用药前一般临床资料比较
组别 例数 性别（例，男性/女性） 年龄（岁，±s） 身高（cm，±s） 体重（kg，±s） 体表面积（m2，±s）
恶性肿瘤组 34 18/16 7.9±3.5 129±19 29±13 1.01±0.27
健康对照组 17 8/9 7.2±3.4 127±24 29±14 1.00±0.34
检验值 ? χ2=0.16 t=0.21 t=0.24 t=0.10 t=0.24
P值 ? 0.69 0.83 0.81 0.92 0.81
表3 恶性肿瘤组与健康对照组患儿用药前常规超声心动图指标比较（±s）
组别 例数 E（m/s） A（m/s） E/A
恶性肿瘤组 34 0.86±0.23 0.60±0.17 1.48±0.37
健康对照组 17 0.85±0.21 0.57±0.17 1.53±0.29
t值 ? 0.23 0.70 0.50
P值 ? 0.82 0.49 0.62
表4 恶性肿瘤组与健康对照组患儿用药前组织多普勒指标比较（±s）
组别 例数 e′（m/s） a′（m/s） s′（m/s） e′/a′ E/e′
恶性肿瘤组 34 0.13±0.02 0.10±0.02 0.12±0.02 1.37±0.28 6.51±1.56
健康对照组 17 0.14±0.03 0.10±0.02 0.11±0.02 1.48±0.22 5.96±1.51
t值 ? 1.18 0.58 1.05 1.35 1.19
P值 ? 0.24 0.56 0.30 0.18 0.24
表5 恶性肿瘤组与健康对照组患儿用药前Tei指数相关指标比较（±s）
组别 例数 ICTR（ms） IRTR（ms） ETR（ms） TeiR ICTS（ms） IRTS（ms） ETS（ms） TeiS Tei指数
恶性肿瘤组 34 50±5 46±7 256±21 0.38±0.03 48±7 47±7 258±17 0.37±0.04 0.37±0.03
健康对照组 17 50±7 42±7 261±22 0.36±0.05 46±8 50±6 256±21 0.37±0.04 0.37±0.03
t值 ? 0.12 1.71 0.71 1.62 0.81 1.37 0.36 0.59 0.63
P值 ? 0.90 0.09 0.48 0.11 0.42 0.18 0.72 0.56 0.53
表6 用药前及不同累计剂量时恶性肿瘤组患儿常规超声指标比较（±s）
组别 例数 E（m/s） A（m/s） E/A
用药前 34 0.86±0.23 0.60±0.17 1.48±0.37
累计剂量100 mg/m2 34 0.83±0.21 0.61±0.17 1.42±0.40
累计剂量200 mg/m2 34 0.83±0.21 0.62±0.14 1.38±0.37
累计剂量250 mg/m2 34 0.84±0.18 0.66±0.16 1.33±0.37
F值 ? 0.195 0.772 0.960
P值 ? 0.900 0.512 0.414
表7 用药前及不同累计剂量时恶性肿瘤组患儿组织多普勒指标比较（±s）
组别 例数 e′（m/s） a′（m/s） s′（m/s） e′ /a′ E /e′
用药前 34 0.13±0.02 0.10±0.02 0.12±0.02 1.37±0.28 6.51±1.56
累计剂量100 mg/m2 34 0.13±0.02 0.10±0.03 0.12±0.02 1.43±0.40 6.45±1.37
累计剂量200 mg/m2 34 0.13±0.02 0.10±0.02 0.12±0.01 1.34±0.31 6.51±1.45
累计剂量250 mg/m2 34 0.13±0.02 0.10±0.02 0.11±0.02 1.36±0.41 6.64±1.35
F值 ? 0.882 0.192 1.257 0.426 0.103
P值 ? 0.452 0.901 0.292 0.736 0.958
表8 用药前及不同累计剂量时恶性肿瘤组患儿Tei指数相关指标比较（±s）
组别 例数 ICTR（ms） IRTR（ms） ETR（ms） TeiR ICTS（ms） IRTS（ms） ETS（ms） TeiS Tei指数
用药前 34 50±5a 46±7 256±21 0.38±0.03b 48±7 47±7 258±17 0.37±0.04 0.37±0.03d
累计剂量100 mg/m2 34 51±5 46±7 256±22 0.38±0.03 49±7 47±7 258±15 0.37±0.04 0.38±0.03
累计剂量200 mg/m2 34 54±5 47±7 255±21 0.40±0.03 49±7 49±7 255±14 0.38±0.04 0.39±0.03
累计剂量250 mg/m2 34 57±5 47±7 254±20 0.41±0.03 51±7 50±7 252±16 0.40±0.04c 0.41±0.03
F值 ? 15.191 0.301 0.098 8.812 1.193 1.387 1.226 4.336 10.296
P值 ? <0.001 0.825 0.961 <0.001 0.315 0.250 0.303 0.006 <0.001
图6 蒽环类药物剂量与Tei指数的相关性
1
Suter TM, Ewer MS. Cancer drugs and the heart: importance and management [J]. Eur Heart J, 2013, 34(15): 1102-1111.
2
Spewak MB, Williamson RS, Mertens AC, et al. Yield of screening echocardiograms during pediatric follow-up in survivors treated with anthracyclines and cardiotoxic radiation [J]. Pediatr Blood Cancer, 2017, 64(6).
3
Mele D, Nardozza M, Spallarossa P, et al. Current views on anthracycline cardiotoxicity [J]. Heart Fail Rev, 2016, 21(5): 621-634.
4
Bloom MW, Hamo CE, Cardinale D, et al. Cancer Therapy-Related Cardiac Dysfunction and Heart Failure: Part 1: Definitions, Pathophysiology, Risk Factors, and Imaging [J]. Circ Heart Fail, 2016, 9(1): e002661.
5
Clasen SC, Wald JW. Left Ventricular Dysfunction and Chemotherapeutic Agents [J]. Curr Cardiol Rep, 2018, 20(4): 20.
6
郑孝志, 季平, 茅红卫. 正常人右心室组织多普勒Tei指数定量分析 [J]. 临床超声医学杂志, 2007, 9(9): 529-531.
7
Keefe DL. Anthracycline-induced cardiomyopathy [J]. Semin Oncol, 2001, 28(4 Suppl 12): 2-7.
8
Zamorano JL, Lancellotti P, Muñoz DR, et al. [2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines] [J]. Kardiol Pol , 2016, 74(11): 1193-1233.
9
Mcgowan JV, Chung R, Maulik A, et al. Anthracycline Chemotherapy and Cardiotoxicity [J]. Cardiovasc Drugs Ther, 2017, 31(1): 63-75.
10
Santin JC, Deheinzelin D, Junior SP, et al. Late echocardiography assessment of systolic and diastolic function of the left ventricle in pediatric cancer survivors after anthracycline therapy [J]. J Pediatr Hematol Oncol, 2007, 29(11): 761-765.
11
Harada K, Tamura M, Toyono M, et al. Effect of dobutamine on a Doppler echocardiographic index of combined systolic and diastolic performance [J]. Pediatr Cardiol, 2002, 23(6): 613-617.
12
Dodos F, Halbsguth T, Erdmann E, et al. Usefulness of myocardial performance index and biochemical markers for early detection of anthracycline-induced cardiotoxicity in adults [J]. Clin Res Cardiol, 2008, 97(5): 318-326.
13
Belham M, Kruger A, Pritchard C. The Tei index identifies a differential effect on left and right ventricular function with low-dose anthracycline chemotherapy [J]. J Am Soc Echocardiogr, 2006, 19(2): 206-210.
14
Bayram C, Çetin İ, Tavil B, et al. Evaluation of Cardiotoxicity by Tissue Doppler Imaging in Childhood Leukemia Survivors Treated with Low-Dose Anthracycline [J]. Pediatr Cardiol, 2015, 36(4): 862-866.
15
Vandecruys E, Mondelaers V, De Wolf D, et al. Late cardiotoxicity after low dose of anthracycline therapy for acute lymphoblastic leukemia in childhood [J]. J Cancer Surviv, 2012, 6(1): 95-101.
16
Kaya F, Arslan D, Vatansev H, et al. Growth-differentiation Factor-15 and Tissue Doppler Imaging in Detection of Anthracycline-induced Cardiomyopathy During Therapy of Childhood Cancers [J]. J Pediatr Hematol Oncol, 2016, 38(3): e107-e112.
17
Szymański P, Rezler J, Stec S, et al. Long-term prognostic value of an index of myocardial performance in patients with myocardial infarction [J]. Clin Cardiol, 2002, 25(8): 378-383.
18
徐欣怡, 黄美蓉, 汤静燕, 等. 蒽环类药物心脏毒性早期监测方法的评价 [J]. 中国当代儿科杂志, 2011, 13(6): 490-494.
19
Kapusta L, Thijssen JM, Grootloonen J, et al. Discriminative ability of conventional echocardiography and tissue Doppler imaging techniques for the detection of subclinical cardiotoxic effects of treatment with anthracyclines [J]. Ultrasound Med Biol, 2002, 27(12): 1605-1614.
20
王雪, 张梅. Tei指数评价心力衰竭患者心室功能 [J/CD]. 中华医学超声杂志(电子版), 2008, 5(4): 40-43.
[1] 张婉微, 秦芸芸, 蔡绮哲, 林明明, 田润雨, 金姗, 吕秀章. 心肌收缩早期延长对非ST段抬高型急性冠脉综合征患者冠状动脉严重狭窄的预测价值[J]. 中华医学超声杂志（电子版）, 2023, 20(10): 1016-1022.
[2] 任书堂, 刘晓程, 张亚东, 孙佳英, 陈萍, 周建华, 龙进, 黄云洲. 左心室辅助装置支持下单纯收缩期主动脉瓣反流的超声心动图特征[J]. 中华医学超声杂志（电子版）, 2023, 20(10): 1023-1028.
[3] 姚宏伟, 魏鹏宇, 高加勒, 张忠涛. 不断提高腹腔镜右半结肠癌D3根治术的规范化[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 1-4.
[4] 杜晓辉, 崔建新. 腹腔镜右半结肠癌D3根治术淋巴结清扫范围与策略[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 5-8.
[5] 杨倩, 李翠芳, 张婉秋. 原发性肝癌自发性破裂出血急诊TACE术后的近远期预后及影响因素分析[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 33-36.
[6] 冯冰, 邹秋果, 梁振波, 卢艳明, 曾奕, 吴淑苗. 老年非特殊型浸润性乳腺癌超声征象与分子生物学指标的临床研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 48-51.
[7] 栗艳松, 冯会敏, 刘明超, 刘泽鹏, 姜秋霞. STIP1在三阴性乳腺癌组织中的表达及临床意义研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 52-56.
[8] 钱龙, 陆晓峰, 王行舟, 杜峻峰, 沈晓菲, 管文贤. 神经系统调控胃肠道肿瘤免疫应答研究进展[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 86-89.
[9] 尚培中, 张润萍, 张伟, 贾国洪, 李晓武, 苗建军, 刘冰. 梗阻性黄疸临床防治新技术单中心应用研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 104-107.
[10] 彭旭, 邵永孚, 李铎, 邹瑞, 邢贞明. 结肠肝曲癌的诊断和外科治疗[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 108-110.
[11] 马伟强, 马斌林, 吴中语, 张莹. microRNA在三阴性乳腺癌进展中发挥的作用[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 111-114.
[12] 曹迪, 张玉茹. 经腹腔镜生物补片修补直肠癌根治术后盆底疝1例[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 115-116.
[13] 李永胜, 孙家和, 郭书伟, 卢义康, 刘洪洲. 高龄结直肠癌患者根治术后短期并发症及其影响因素[J]. 中华临床医师杂志(电子版), 2023, 17(9): 962-967.
[14] 袁媛, 赵良平, 刘智慧, 张丽萍, 谭丽梅, 閤梦琴. 子宫内膜癌组织中miR-25-3p、PTEN的表达及与病理参数的关系[J]. 中华临床医师杂志(电子版), 2023, 17(9): 1016-1020.
[15] 刘笑笑, 张小杉, 刘群, 马岚, 段莎莎, 施依璐, 张敏洁, 王雅晳. 中国学龄前儿童先天性心脏病流行病学研究进展[J]. 中华临床医师杂志(电子版), 2023, 17(9): 1021-1024.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号